FyoniBio and Strike Pharma Successfully Complete Cell Line Development for Bi-specific Antibody Clinical Candidate
FyoniBio and Strike Pharma announce the successful completion of a key milestone in the development of Strike’s innovative bi-specific mAb candidate. Using FyoniBio’s CHOnamite® platform, the final production clone achieved high titer and robust stability, paving the way for clinical manufacturing.
